Clinical Trials Browser

Phase 1/2 × Cholangiocarcinoma × pembrolizumab × Clear all

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05732831 2025-11-14

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05220722 2025-10-23

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 1/2 Active not recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03937895 2022-03-29

Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer

Phase 1/2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma